skip to Main Content

Dr. Botta on the Evaluation of CT041 in Gastric and Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
Gregory Botta, MD, PhD, medical oncologist, associate professor of medicine, University of California, San Diego Health (UCSD), discusses the evaluation of CT041 in patients with advanced gastric and pancreatic cancers in a phase 1b trial (NCT04404595).

In the open label, multi-center study, investigators evaluated CT041, a CAR T-cell therapy that targets Claudin18.2 (CLDN18.2).Heavily pretreated patients in the population were able to achieve responses up to 60% in the salvage line setting, Botta says. Moreover, patients who have been on multiple lines of chemotherapy and present with various comorbidities were able to safely complete the CAR T-cell therapy and lymphodepletion, Botta explains. Read more . . . 


Back To Top